Mirum Says LIVMARLI Phase 3 EXPAND Study Met Primary Endpoint
Mirum Pharmaceuticals announced topline results from its Phase 3 EXPAND study of LIVMARLI (maralixibat) in patients with ultra-rare cholestatic liver diseases, reporting that the primary endpoint was met.
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a leading rare disease company, today announced topline results from the Phase 3 EXPAND study evaluating LIVMARLI® (maralixibat) for the treatment of cholestatic pruritus in patients aged 6 months or older with ultra-rare cholestatic liver diseases, includ…